Oral Paricalcitol versus Calcitriol in Peritoneal Dialysis Patients: effects on peritoneal transport and peritoneal defence

Oral Paricalcitol versus Calcitriol in Peritoneal Dialysis Patients: effects on peritoneal transport and peritoneal defence - Paricalcitol in PD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON37926

Enrollment

Registered

2011-03-14

Start date

2011-05-25

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Verstoring peritoneale homeostase door peritoneaaldialyse Peritoneal damage due to peritoneal dialysis

Interventions

Calcitriol or paricalcitol after a wash-out period (see study design).

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: · the patient must provide written consent prior to starting the study · patients must be over 18 years of age · patients must have CKD stage 5 and treatment with peritoneal dialysis · indication for active vitamin D therapy based on prevailing guidelines (after 6 weeks of wash-out) · Calcium, corrected to albumen,

Exclusion criteria

Exclusion criteria: · Patients who do not meet the specific inclusion criteria. · UF

Design outcomes

Primary

Measure	Time frame
Endpoints are differences (25% or more) in markers of inflammation and peritoneal transport between the paricalcitol and alphacalcidol groups.	—

Secondary

Measure	Time frame
None	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)